<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0016-3813</journal-id>
<journal-title><![CDATA[Gaceta médica de México]]></journal-title>
<abbrev-journal-title><![CDATA[Gac. Méd. Méx]]></abbrev-journal-title>
<issn>0016-3813</issn>
<publisher>
<publisher-name><![CDATA[Academia Nacional de Medicina de México A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0016-38132025000300006</article-id>
<article-id pub-id-type="doi">10.24875/gmm.25000006</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Costo-efectividad del tratamiento dual con metformina-sitagliptina frente a metformina-dapagliflozina en pacientes con diabetes tipo 2]]></article-title>
<article-title xml:lang="en"><![CDATA[Cost-effectiveness of dual treatment with metformin-sitagliptin versus metformin- dapagliflozin in patients with type 2 diabetes]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cruz-Gallegos]]></surname>
<given-names><![CDATA[Linda A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Villarreal-Ríos]]></surname>
<given-names><![CDATA[Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Blanco-Castillo]]></surname>
<given-names><![CDATA[Leticia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Galicia-Rodríguez]]></surname>
<given-names><![CDATA[Liliana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Unidad de Medicina Familiar No. 9 ]]></institution>
<addr-line><![CDATA[Querétaro ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Unidad de Investigación Epidemiológica y en Servicios de Salud ]]></institution>
<addr-line><![CDATA[Querétaro ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Unidad de Medicina Familiar No 11 ]]></institution>
<addr-line><![CDATA[Querétaro ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2025</year>
</pub-date>
<volume>161</volume>
<numero>3</numero>
<fpage>282</fpage>
<lpage>288</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0016-38132025000300006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0016-38132025000300006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0016-38132025000300006&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes: Para el manejo de la diabetes se han introducido nuevos hipoglucemiantes de alto costo para la atención médica en primer nivel. La evaluación de costo-efectividad permite el análisis conjunto de los componentes económico y epidemiológico.  Objetivo: Determinar el costo-efectividad del tratamiento dual con metformina + sitagliptina en comparación con metformina + dapagliflozina en el paciente con diabetes tipo 2.  Material y métodos: Estudio de costo-efectividad, con dos grupos de pacientes con diabetes tipo 2 de 30 a 64 años en tratamiento dual, con metformina + sitagliptina o con metformina + dapagliflozina. Se estudió el costo unitario fijo y variable; el costo variable promedio se estimó con la técnica de microcosteo, y el costo fijo promedio con la técnica de tiempos y movimientos. El costo promedio anual se integró con los costos variables y fijos promedio. La relación costo-efectividad se estimó para $4000 y se realizaron proyecciones del costo-efectividad.  Resultados: El control glucémico (efectividad) para metformina + dapagliflozina fue del 42.10% y para metformina + sitagliptina del 26.50%. En el escenario promedio, el costo promedio anual para metformina + dapagliflozina fue $3598.52 y para metformina + sitagliptina $5746.82. Con una inversión de $4000 se obtiene una efectividad del 46.80% en el grupo de metformina + dapagliflozina y del 18.44% en el de metformina + sitagliptina.  Conclusiones: En los pacientes con diabetes tipo 2, metformina + dapagliflozina alcanza la mejor relación costo-efectividad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: And new high-cost antihyperglycemic agents have been introduced into the basic medical at primary care level for its management. The cost-effectiveness evaluation allows the economic and epidemiological components to be analysed together.  Objective: To determine the cost-effectiveness of dual therapy with metformin + sitagliptin versus metformin + dapagliflozin in patients with type 2 diabetes.  Material and methods: Economic cost-effectiveness study with two groups of patients with type 2 diabetes aged 30 to 64 years in dual treatment, metformin + sitagliptin versus metformin + dapagliflozin. The fixed and variable unit costs were examined; the average variable cost was estimated using the microcost technique, and the average fixed cost was estimated using the time and motion technique. The average annual cost was integrated with the average variable and fixed costs. The cost-effectiveness ratio was estimated at $4000 and cost-effectiveness projections were made.  Results: Glycaemic control (efficacy) was 42.10% for metformin + dapagliflozin and 26.50% for metformin + sitagliptin. In the intermediate scenario, average annual costs were $3598.52 for metformin + dapagliflozin and $5,746.82 for metformin + sitagliptin. For an investment of $4000, the effectiveness of the metformin + dapagliflozin group was 46.80%, and the effectiveness of the metformin + sitagliptin group was 18.44%.  Conclusions: In patients with type 2 diabetes, metformin + dapagliflozin achieves the best cost-effectiveness ratio.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Metformina]]></kwd>
<kwd lng="es"><![CDATA[Sitagliptina]]></kwd>
<kwd lng="es"><![CDATA[Dapagliflozina]]></kwd>
<kwd lng="es"><![CDATA[Costo-efectividad]]></kwd>
<kwd lng="es"><![CDATA[Control glucémico]]></kwd>
<kwd lng="es"><![CDATA[Diabetes tipo 2]]></kwd>
<kwd lng="en"><![CDATA[Metformin]]></kwd>
<kwd lng="en"><![CDATA[Sitagliptin]]></kwd>
<kwd lng="en"><![CDATA[Dapagliflozin]]></kwd>
<kwd lng="en"><![CDATA[Cost-effectiveness]]></kwd>
<kwd lng="en"><![CDATA[Glycemic control]]></kwd>
<kwd lng="en"><![CDATA[Diabetes type 2]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Organización Panamericana de la Salud</collab>
<source><![CDATA[Panorama de la diabetes en la Región de las Américas]]></source>
<year>2023</year>
<publisher-loc><![CDATA[Washington, D. C ]]></publisher-loc>
<publisher-name><![CDATA[Organización Panamericana de la Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Basto Abreu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[López Olmedo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Rojas Martínez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar Salinas]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno Banda]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Carnalla]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de prediabetes y diabetes en México:Ensanut 2022]]></article-title>
<source><![CDATA[Salud Publica Mex]]></source>
<year>2023</year>
<volume>65</volume>
<numero>Supl 1</numero>
<issue>Supl 1</issue>
<page-range>S163-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<collab>International Diabetes Federation</collab>
<source><![CDATA[IDF Diabetes Atlas]]></source>
<year>2021</year>
<edition>10th edition</edition>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castro Ríos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nevárez Sida]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tiro Sánchez]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Wacher Rodarte]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Triggering factors of primary care costs in the years following type 2 diabetes diagnosis in Mexico]]></article-title>
<source><![CDATA[Arch Med Res]]></source>
<year>2014</year>
<volume>45</volume>
<page-range>400-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association Professional Practice Committee</collab>
<article-title xml:lang=""><![CDATA[Pharmacologic approaches to glycemic treatment:standards of medical care in diabetes - 2022]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2022</year>
<volume>45</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>S125-43</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rojas-Velasco]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Solis]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gaona]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nunes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Evaluación de Sitagliptina para el tratamiento de pacientes adultos con diabetes mellitus tipo 2:revisión sistemática de costo-efectividad]]></source>
<year>2020</year>
<volume>45</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>8-20</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Drummond]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[O'Brien]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Stoddart]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Torrance]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
</person-group>
<source><![CDATA[Métodos para la evaluación económica de los programas de asistencia sanitaria]]></source>
<year>2001</year>
<edition>2.ªed</edition>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Díaz de Santos]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vanegas]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La economía de la salud en México]]></article-title>
<source><![CDATA[Revista de la CEPAL]]></source>
<year>2020</year>
<volume>132</volume>
<page-range>196-208</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<collab>Asamblea Mundial de la Salud</collab>
<source><![CDATA[Seguimiento de la declaración política de la tercera reunión de alto nivel de la Asamblea General sobre la prevención y el control de las enfermedades no transmisibles]]></source>
<year>2022</year>
<publisher-name><![CDATA[Organización Mundial de la Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>Instituto Mexicano del Seguro Social</collab>
<source><![CDATA[Cuadro Básico de Medicamentos Instituto Mexicano del Seguro Social;971 Claves Específicas]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<collab>Instituto Mexicano del Seguro Social</collab>
<source><![CDATA[Protocolos de Atención Integral. Diabetes mellitus tipo 2. Prevención, diagnóstico y tratamiento]]></source>
<year>2022</year>
<publisher-name><![CDATA[Instituto Mexicano del Seguro Social]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Atonal-Flores]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[León-Vázquez]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Barranco-Juárez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Indicadores de diabetes mellitus posterior a liraglutida, sitagliptina/metformina, linagliptina y sitagliptina]]></article-title>
<source><![CDATA[Rev Med Inst Mex Seguro Soc]]></source>
<year>2023</year>
<volume>61</volume>
<page-range>489-95</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez-Lozano]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Camarillo-Nava]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
<name>
<surname><![CDATA[Juárez-Zepeda]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade-Pineda]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Lucho-Gutiérrez]]></surname>
<given-names><![CDATA[ZM]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes-Pacheco]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Costo-efectividad del tratamiento de la diabetes mellitus tipo 2 en México]]></article-title>
<source><![CDATA[Rev Med Inst Mex Seguro Soc]]></source>
<year>2023</year>
<volume>61</volume>
<page-range>172-80</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[D'Andrea]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Wexler]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Paik]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Alt]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Patorno]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1clevels]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2023</year>
<volume>183</volume>
<page-range>242</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abad Paniagua]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Casado Escribano]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández Rodriguez]]></surname>
<given-names><![CDATA[J M]]></given-names>
</name>
<name>
<surname><![CDATA[Morales Escobar]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Betegón Nicolás]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Covisa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Análisis de coste-efectividad de dapagliflozina en comparación con los inhibidores de la DPP4 y otros antidiabéticos orales en el tratamiento de la diabetes mellitus tipo 2 en España]]></article-title>
<source><![CDATA[Aten Primaria]]></source>
<year>2015</year>
<volume>47</volume>
<page-range>505-13</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gay]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Prada]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Análisis de costos y beneficios clínicos de dapaglifozina vs iDPP-4:adaptación en México del estudio CVD-REAL Nordic]]></article-title>
<source><![CDATA[Latin American Journal of Clinical Sciences and Medical Technology]]></source>
<year>2020</year>
<volume>2</volume>
<page-range>242-50</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
